Organovo Holdings, Inc.s in-depth stock price analysis indicates that the stock price has rallied 0.63% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -17.78% . Looking at the past 52 week period, the stock price is up at 68.78% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Organovo Holdings, Inc. has a positive value of 56.22 compared to overall market. Organovo Holdings, Inc. (NASDAQ:ONVO) has tumbled 13.78% during the past week and has dropped 13.78% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 14.48%. Organovo Holdings, Inc. (NASDAQ:ONVO) has underperformed the index by 15.33% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Organovo Holdings, Inc. (NASDAQ:ONVO) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.58 points or 15.38% at $3.19 with 5,609,809 shares getting traded. Post opening the session at $3.25, the shares hit an intraday low of $3.14 and an intraday high of $3.3 and the price was in this range throughout the day. The company has a market cap of $333 million and the number of outstanding shares has been calculated to be 104,410,605 shares. The 52-week high of Organovo Holdings, Inc. (NASDAQ:ONVO) is $4.99 and the 52-week low is $1.7875.
Organovo Holdings Inc Last issued its quarterly earnings results on Feb 9, 2017. The company reported $-0.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.10. The company had revenue of $1.15 million for the quarter, compared to analysts expectations of $1.40 million. The companys revenue was up 248.5% compared to the same quarter last year.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Organovo Holdings Inc was Initiated by Raymond James to Outperform on Jan 25, 2017.
Company has reported several Insider transactions to the SEC, on Jan 25, 2017, Keith Murphy (Chairman, CEO and President) sold 25,000 shares at 3.51 per share price.On Aug 9, 2016, Eric David (CSO & EVP Pre-Clinical Dev) sold 20,000 shares at 4.55 per share price.On Sep 23, 2015, Robert Jr. Baltera (director) sold 6,000 shares at 4.03 per share price.
Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California.